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deals with a variety of aspects in patients with atrial fibrilla-
tion, including stroke. At the recent American Stroke Associ-
ation's International Stroke Conference 2012, held in New
Orleans, USA from 1 to 3 February, several very interesting
presentations around the themes atrial fibrillation and stroke
were given. In the first presentation it was reported that the use
of outpatient cardiac telemetry over 21 days allowed the
detection of occult paroxysmal atrial fibrillation in almost
20% of patients with cryptogenic stroke. Data were obtained
from 156 patients (mean age 68.5 years) evaluated by mobile
cardiac outpatient telemetry monitoring within 6 months of a
cryptogenic stroke or transient ischaemic attack (TIA). It
was reported that the detection of paroxysmal atrial
fibrillation significantly increased from 3.8% in the initial 48
hours, to 9.2% at 7 days, to 15.1% at 14 days, and to 19.5% by
21 days (p<0.05).
In the second presentation on improving early diagnosis of
stroke it was reported that CT angiography (CTA) imaging
should be included with brain CT (dual imaging) for early
detection of severe arterial stenosis in patients presenting with
TIA or minor stroke. It was found that of 491 patients with
TIA or minor stroke, the median time to a recurrent stroke was
one day, but the median time from stroke onset to CTA
imaging was 5.5 hours versus 17.5 hours for diffusion-
weighted magnetic resonance imaging.
an analysis of postmenopausal women identified novel lipid
and lipoprotein biomarkers associated with the risk of ischae-
mic stroke. Baseline triglycerides, very-low-density lipopro-
tein size, and intermediate-density lipoprotein particle number
were associated with an increased risk of ischaemic stroke.
This suggests that new therapeutics targeting these lipids and
lipoproteins might confer better risk protection.
At the therapeutic level, it was reported that warfarin was
statistically equal to aspirin in reducing death or stroke in
heart failure patients, but increased gastrointestinal bleeds. It
was found that of the 2305 patients randomised to warfarin
or aspirin, warfarin conferred a non-significant 7% reduced
risk of the primary outcome of death or stroke at a mean
follow-up of 6 years.
Another presentation, at the therapeutic level, showed
that combining clopidogrel (Plavix) with aspirin did not
prevent recurrent stroke deep in the brain, and even in-
creased the risk of bleeding and death, according to a
double-blind, randomised trial that was prematurely discon-
tinued. Patients receiving the dual antiplatelet therapy had a
2.1% risk of major bleeding—which is almost twice the
1.1% risk of those on aspirin plus placebo (p<0.001). It
was also demonstrated that the annual risk of all-cause death
was greater with the combined therapy, i.e. 2.1% for aspirin
plus clopidogrel compared with 1.4% for aspirin plus placebo
(p00.005).
A more positive presentation on therapeutic approaches in
stroke showed that dabigatran (Pradaxa) was more cost-
effective than warfarin at preventing stroke in atrial fibrillation
patients who have had a prior stroke or TIA. Dabigatran
provided 0.36 more qualityadjusted life-years (QALY) than
warfarin. It was reported that the cost for those additional
QALY was $9000, translating into an incremental cost-
effectiveness ratio of $25,000.
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With respect to atrial fibrillation per se, it was shown that
older individuals with higher levels of omega-3 fatty acids
may face a lower risk of developing atrial fibrillation. The
researchers looked at blood samples from approximately
3300 individuals.
In one of the final presentations it was reported that,
surprisingly, nearly half (47%) of stroke survivors may have
poorly controlled hypertension. The study involved almost
500 adult stroke survivors who participated in a national
survey from 1999 to 2004. Therefore, hypertension post-
stroke should be carefully watched and treated accordingly.
Based on the increased rate of strokes and heart attacks,
the Million Hearts initiative has been launched in the USA.
The goal of the Million Hearts initiative is to reduce the rate
of heart attacks and strokes by one million events in the
USA over the next 5 years. The initiative was rolled out in
September 2011 by the US Health and Human Services
department, and supported (among others) by the American
College of Cardiology.
Such initiatives have also grounded in Europe. At the end
of 2010, the European Society of Cardiology (ESC) pub-
lished new guidelines for management of atrial fibrillation
and stroke risk. The Pan-European Stroke Prevention in
Atrial Fibrillation Registry—PREFER in AF—enrolled its
first patient on 16 January 2012. The European Stroke
Organisation (ESO) aims at the development of public poli-
cies to reduce the number of stroke-associated deaths and the
reduction of the global burden caused by stroke throughout
Europe. Lastly, the Stroke Alliance for Europe (SAFE) repre-
sents a strong patient voice which will call on European
Governments to take the lead in making stroke prevention a
health priority. Based on the new insights, these initiatives
have become an utmost need.
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